Cross sections and calculated yields of some radionuclides of yttrium, strontium and rubidium formed in proton-induced reactions on enriched strontium-86: possibility of production of 85gSr, 83Rb and 82mRb in no-carrier-added form
Author:
Uddin M. Shuza12, Basunia M. Shamsuzzoha3, Spahn Ingo1, Spellerberg Stefan1, Khan Rahat2, Uddin M. Mezbah4, Bernstein Lee A.35, Neumaier Bernd1, Qaim Syed M.1
Affiliation:
1. Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich , D-52425 Jülich , Germany 2. Institute of Nuclear Science and Technology, Atomic Energy Research Establishment , Savar , Dhaka , Bangladesh 3. Nuclear Science Division, Lawrence Berkeley National Laboratory , Berkeley , CA 94720 , USA 4. Centre for Research Reactor, Atomic Energy Research Establishment , Savar , Dhaka , Bangladesh 5. Department of Nuclear Engineering, UC Berkeley , Berkeley , CA 94720 , USA
Abstract
Abstract
Cross sections of the 86Sr(p,3n)84mY, 86Sr(p,αn)82mRb, and 86Sr(p,x)85gSr reactions were measured from their respective thresholds up to 16.2 MeV and from 23.0 to 44.1 MeV at FZJ, and from 14.3 to 24.5 MeV at LBNL, using 96.4% enriched 86SrCO3 as target material. Thin targets prepared by sedimentation were irradiated with protons in a stacked-form, and the induced radioactivity was measured by high-resolution γ-ray spectrometry. Nuclear model calculations based on the code TALYS reproduced our experimental cross section data well. From the excitation functions, the integral yields of the above three radionuclides were calculated. The yield of 85gSr via the natSr(n,γ) process was also measured using the TRIGA Mark-II reactor at AERE, Savar. A comparison of the reactor and cyclotron production of carrier-added 85gSr is given. The production possibilities of the three investigated radionuclides in no-carrier-added forms at a 30 MeV cyclotron via new routes are discussed.
Publisher
Walter de Gruyter GmbH
Subject
Physical and Theoretical Chemistry
Reference31 articles.
1. Qaim, S. M. Medical Radionuclide Production–Science and Technology; De Gruyter: Berlin/Boston, 2020; pp. 1–288. 2. Radioisotopes in Medicine; World Nuclear Association: Tower House, London, UK. world-nuclear.org/Information-Library/Non-power-nuclear-applications/Radioisotopes-Research/Radioisotopes-in-Medicine.aspx (accessed Apr, 2022). 3. Qaim, S. M., Scholten, B., Neumaier, B. New developments in the production of theranostic pairs of radionuclides. J. Radioanal. Nucl. Chem. 2018, 318, 1493–1509; https://doi.org/10.1007/s10967-018-6238-x. 4. Rösch, F., Herzog, H., Qaim, S. M. The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y. Pharmaceuticals 2017, 10, 56; https://doi.org/10.3390/ph10020056. 5. Uddin, M. S., Scholten, B., Basunia, M. S., Sudár, S., Spellerberg, S., Voyles, A. S., Morrell, J. T., Zaneb, H., Rios, J. A., Spahn, I., Bernstein, L. A., Qaim, S. M., Neumaier, B. Accurate determination of production data of the non-standard positron emitter 86Y via the 86Sr(p,n)-reaction. Radiochim. Acta 2020, 108, 747–756; https://doi.org/10.1515/ract-2020-0021.
|
|